Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Kalam-Institute-of-Health-Technology"

2 News Found

Can India become global clinical trials hub? Industry leaders to discuss road ahead on 19th June
News | June 17, 2026

Can India become global clinical trials hub? Industry leaders to discuss road ahead on 19th June

Leading experts from AIIMS Kalyani, Syngene, Veeda Lifesciences, Lambda Therapeutic, DNDi, JSS Medical, KIHT, InoRx, ISCR and SIRO Clintech to discuss India’s readiness as preferred clinical research destination

Govt approval to KIHT as CRO expands India’s innovation capabilities
Clinical Trials | June 12, 2026

Govt approval to KIHT as CRO expands India’s innovation capabilities

KIHT can now conduct clinical research for drugs and medical devices, strengthening evidence generation and healthcare innovation

Upcoming E-conference
July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

AngioDynamics gets FDA nod for RELIEF trial to evaluate NanoKnife for enlarged prostate treatment

Apollo Hospitals Seshadripuram expands cardiac care capacity with second Cath Lab

Brooks Instrument launches ultra-compact advanced mass flow controller for research applications

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Dr. Manjiri Bakre CEO and Founder, OncoStem Diagnostics
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
Akhil Ravi Chief Executive Officer, Aurigene Pharmaceutical Services Limited
Our D2 lamp portfolio caters to entire spectrum of chromatography and spectroscopy customers: Hemang Jhaveri, Partner, Hiten Techno Products Corporation
Our D2 lamp portfolio caters to entire spectrum of chromatography and spectroscopy customers: Hemang Jhaveri, Partner, Hiten Techno Products Corporation

Packaging